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PSY62
HEALTH TECHNOLOGY ASSESSMENT FOR RARE DISEASES: A 
MARKOVIAN MODEL FOR FABRY DISEASE (FD) CONSIDERING ENZYME 
REPLACEMENT THERAPY(ERT)
Vinhas de Souza M1, Schwartz I2
1Universidade Federal do Rio Grande do Sul/UFRGS, Porto Alegre, RS, Brazil; 2Universidade 
Federal do Rio Grande do Sul/UFRGS and HCPA, Porto Alegre, RS, Brazil
OBJECTIVES: Evaluate, using a markovian probabilistic model, the development of 
renal disease in Fabry Disease(FD), comparing the probability of developing the dif-
ferent stages of renal disease in those with FD using Enzyme replacement therapy 
(ERT) with those not using ERT. METHODS: A model with pre-deﬁ ned 3 possible 
stages was used for patients with FD and renal dysfunction. Progression to a different 
stage or having a stable disease were possible. Less severe ‘stages’ could only migrate 
to more severe ‘stages’. Three year time cycles were used. The probabilities ERT x 
without ERT were compared. RESULTS: Probabilities between the 2 arms: 1)The 
probability of having proteinuria only and being stable in 3 y was 56% in those treated 
versus 48% in those untreated; 2)Also for those with proteinuria only, with ERT the 
probability of progressing to renal impairment in 3 y was reduced, to 24% compared 
to 32% in those untreated; and 3)For those receiving ERT already with renal impair-
ment, but not in dialysis, the probability of postponing the dialysis in 3 y time was 
not modiﬁ ed. CONCLUSIONS: This model did show a relevant improvement with 
ERT for those that were treated at initial stages of renal disease (the subgroup with 
proteinuria only). For this group the probability of remaining in a less severe stage of 
the disease in a 3 y time, postponing renal impairment was signiﬁ cant for those using 
ERT. This was only a preliminar model, considering that the maintenance of less 
severe states of renal disease postpone the need for dialysis in this sub-group, aspects 
such as quality of life will be added in order to do a more complete evaluation. This 
model was build considering clinical outcomes, something new on rare diseases. The 
discussion on how to evaluate and on the value of ‘classical modeling’ in rare diseases 
are still an on going issue with a lot to be elucidated.
PSY63
WORK AND DAILY ACTIVITY IMPAIRMENT IN PATIENTS WITH 
DIGITAL ULCERS (DUS)—RESULTS FROM THE DUO REGISTRY
Hunsche E1, Denton C2, Krieg T3, Guillevin L4, Schwierin B1, Matucci-Cerinic M5
1Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; 2Royal Free Hospital, London, UK; 
3University of Koln, Koln, Germany; 4University Paris, Paris, France; 5University of Florence, 
Florence, Italy
BACKGROUND: Digital ulcers (DU) are difﬁ cult to heal, and can lead to severe, 
disabling complications. The DUO Registry is an international, multi-centre, observa-
tional study to assess outcomes in patients with DU disease associated with Sclero-
derma. OBJECTIVES: To assess the impact of DU on patients’ work, daily activities, 
and dependency. METHODS: A work and daily activities assessment questionnaire 
was completed by the patients at enrollment visit into the DUO registry from April 
2008 to April 2010. An overall score measuring the impairment in daily activities and 
in work was calculated. In addition, the number of hours of help needed was deter-
mined. Overall mean (SD) as well as stratiﬁ ed analyses by number of DU were per-
formed. RESULTS: At the cut-off date for this analysis, 1770 questionnaires were 
received from patients enrolled in the registry. The questionnaire was completed by 
71% (n = 1250), of which 35% patients were employed. The majority of patients 
completing the questionnaire were female (82%) with a mean age of 54 years. Prob-
lems associated with DU reduced the ability of patients to perform regular daily 
activities by 52% (SD 30). More than 50% of the patients needed help due to their 
DU during the previous month, with an average of 7 hours (SD 29) of paid help and 
36 hours (SD 101) of unpaid help. The productivity of patients working was reduced 
by 40% (SD 31). Patients with one or more DU present at enrolment and completing 
the questionnaire (72% of all completers) were more impaired in their daily activities 
(38%, 52%, 55%, 63% for patients with 0, 1, 2, ≥3 DUs, respectively) and work 
(32%, 40%, 41%, 47% for patients with 0, 1, 2, ≥3 DU, respectively). CONCLU-
SIONS: DU impose a signiﬁ cant burden on patients’ by impacting their daily life and 
ability to work as shown in patients enrolled in the DUO Registry.
PSY64
SEQUENCE OF TREATMENT IN IMMUNE THROMBOCYTOPENIA (ITP) 
PATIENTS: RESULTS OF A MEDICAL RECORD REVIEW FROM EIGHT 
HOSPITALS IN SPAIN
Sanz MÁ1, Jarque I1, Yuste VJ2, Julià A3, Gómez RV4, García CG5, Mateos MV6, Montero 
EO7, Páramo JA8, Mathias SD9
1University Hospital La Fe, Valencia, Spain; 2University Hospital La Paz, Madrid, Spain; 
3University Hospital Vall d’Hebron, Barcelona, Spain; 4C. H. U. a Coruña, a Coruña, Spain; 
5H. U. 12 de Octubre, Madrid, Spain; 6H. Clínico Salamanca, Salamanca, Spain; 7H. U. 
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OBJECTIVES: To better understand current practice patterns and determine how 
current practice ﬁ ts recently published guidelines, a treatment sequencing analysis of 
ITP patients in Spain was conducted. METHODS: A retrospective chart review of 
patients diagnosed with ITP was undertaken at 8 hospitals in Spain, collecting demo-
graphic and clinical data, drug treatment (up to ﬁ fth line) and its duration. Throm-
bopoetin-receptor agonists were not available at the time of the review. RESULTS: 
Data on 60 patients [90% (n = 54) with baseline platelet counts <30 × 109/L and 10% 
(n = 6) <50 × 109/L with bleeding episodes] were available. Patients were 54.4 ± 20.7 
(SD) years of age, 63% female, and 6.0 ± 7.2 (SD) years since diagnosis. The most 
common ﬁ rst-line treatment was corticosteroids (n = 39, 65%), followed by intrave-
nous immunoglobulins (IVIg; n = 19, 32%). The mean duration of ﬁ rst-line treatment 
with corticosteroids was 28.2 ± 39.0 (SD) days. The most common sequence of treat-
ment for patients initially treated with corticosteroids was administration of four 
additional courses with corticosteroids (18/39, 46%), followed by alternation between 
IVIg and corticosteroids until the ﬁ fth-line of treatment (7/39, 18%). Of the 19 
patients with initial IVIg, 5 (26%) received corticosteroids in the 4 remaining treat-
ments, 5 (26%) continued with IVIg, and 4 (21%) alternated corticosteroids and IVIg. 
In total, 41 patients (68%) received ≥2 treatments with corticosteroids and 10 (17%) 
received treatments other than corticosteroids and IVIg (3 patients received azathio-
prine, 3 rituximab, 2 platelet transfusions, 1 anti-D immunoglobulin, 1 danazol and 
1 mycophenolate mofetil). CONCLUSIONS: Patterns of treatment of ITP in Spain 
usually followed recently introduced recommendations from international consensus 
guidelines. However, in most patients, corticosteroid treatment was given repeatedly, 
which exceeds current recommendations, i.e., rapidly tapering corticosteroid dose and 
stopping after 4 weeks. Future research is needed with a larger sample size, to explore 
the place of splenectomy in treatment sequencing, and better understand the role of 
combination therapy. 
SYSTEMIC DISORDERS/CONDITIONS – Conceptual Papers & Research on 
Methods
PSY66
WEB VERSUS FACE-TO-FACE (FTF) ADMINISTRATION OF A HEALTH 
UTILITY SURVEY IN THE GENERAL PUBLIC: RESULTS FROM A TIME 
TRADE-OFF (TTO) SURVEY ON IDIOPATHIC THROMBOCYTOPENIC 
PURPURA (ITP)
Szende A1, Schaefer C2, Brazier J3
1Covance, Leeds, West Yorkshire, UK; 2Covance, Gaithersburg, MD, USA; 3University of 
Shefﬁ eld, Shefﬁ eld, UK
OBJECTIVES: Web-based administration of health utility interviews offers the poten-
tial to recruit larger, more representative samples with reduced time and costs com-
pared to FTF administration. This analysis compared health utilities elicited through 
web vs. FTF administration. METHODS: Six distinct ITP health states were included 
in a TTO and visual analogue scale (VAS)-based health utility valuation, which was 
administered FTF (n = 63) and via web (n = 359) to members of the UK general public. 
The Wilcoxon rank-sum test was used to compare utilities between methods. The 
interaction between administration method and respondent characteristics was 
assessed by regression analyses on each pair of health utilities. An additional analysis 
of exclusion criteria was conducted from least strict to most strict. RESULTS: Demo-
graphic characteristics in the FTF and web survey were generally comparable to the UK 
general population 2001 census data. The mean time to complete the TTO survey was 
10.2 minutes in the FTF and 9.9 minutes in the web survey. Valid TTO response rates 
were higher in the FTF sample (85% to 96%) compared to the web sample (58% to 80%) 
across health states. Higher proportions of web respondents reported that the TTO 
exercise was ‘very’ or ‘somewhat unclear’ (17 % vs. none) or that all or most decisions 
were difﬁ cult to make (41% vs. 30%) compared to the FTF sample. Utilities were statisti-
cally signiﬁ cantly lower in the web vs. the FTF survey (P < 0.05). TTO scores were sensitive 
to the selection of exclusion criteria. The variation in TTO scores was smaller among FTF 
vs. web respondents. VAS ratings were similar across the two administration methods and 
less sensitive to exclusion criteria selection. CONCLUSIONS: Our study highlighted 
trade-offs between the advantages and challenges of web administration. More 
research is warranted to further improve data quality in web-based utility surveys.
PSY67
PREDICTING EQ-5D UTILITIES FROM NEUROPATHIC PAIN SCORES: 
COMPARING INDIRECT MAPPING OF PREDICTED ITEM RESPONSES 
WITH DIRECT MAPPING OF SCORES
Gu NY1, Bell C2, Ji X1, Carter J1, Botteman M1, Van Hout BA3
1Pharmerit North America, LLC, Bethesda, MD, USA; 2GlaxoSmithBell, Research Triangle 
Park, NC, USA; 3University of Shefﬁ eld, Shefﬁ eld, UK
OBJECTIVES: To predict EQ-5D utilities from neuropathic pain scores using indirect 
mapping of pain scores to EQ-5D item responses subsequently converted into utilities 
or direct mapping of pain scores into utilities. METHODS: Mappings were based on 
baseline data from three longitudinal surveys of adults (n = 2,719) who had ≥3 months 
of painful diabetic peripheral neuropathy (pDPN) or post-herpetic neuralgia (PHN), 
were receiving pain medications, and completed EQ-5D and pain questionnaires. In 
indirect mapping, ordered logit regression was used to predict and simulate EQ-5D 
responses using the following predictors: age, gender, and pain scores ranging from 0 
(“no pain”) to 10 (“pain as bad as you can imagine”). Utilities were computed based 
on predicted responses using a U.S. algorithm. In direct mapping, OLS regression was 
used to directly predict utilities using the same predictors. Cross-validations were 
conducted separately in pDPN and PHN respondents. Comparisons were made 
between actual and estimated values on mean utilities, mean square/absolute errors 
(MSE/MAE). RESULTS: Both estimated utilities were consistent with actual values 
along the increment/decrement of the pain scores. Direct mapping explained 29% of 
the variance and had an estimated mean utility close to the observed data [0.594 (MSE 
= 0.31; MAE = 0.148)]. Indirect mapping resulted in lower mean utility [0.588 (MSE 
= 0.054; MAE = 0.184)] but its distribution was more consistent with the actual values. 
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Higher MSEs found in indirect mapping were mostly pronounced in lower utilities 
(<0.2). Predicted utilities were slightly higher than actual values when population 
average was used for input (0.3–3%). Similar ﬁ ndings were noted in sub-samples. 
CONCLUSIONS: Both methods produced robust results. Compared to direct 
mapping, indirect mapping better represents the EQ-5D’s descriptive information, 
although with higher MSE/MAE. This research provides algorithms for estimating 
EQ-5D item responses and utilities on the basis of pain scores in absence of direct 
utility evidence. Further investigation using out-of-sample predictions is encouraged.
PSY68
HEPATITIS C-SPECIFIC QUALITY OF LIFE IS NOT PROPERLY 
MEASURED BY EXISTING INSTRUMENTS
Duracinsky M, Armstrong AR, Lalanne C, Chassany O
Assistance Publique-Hopitaux de Paris, Paris, France
OBJECTIVES: Measures commonly used in Hepatitis C (HCV) Health-Related 
Quality of Life (HRQL) research were investigated to determine whether they effec-
tively encompass the disease-speciﬁ c experience of HCV. METHODS: Important 
HCV HRQL dimensions were identiﬁ ed via a review of qualitative and quantitative 
literature. Medline and Embase were interrogated for appropriate studies. Quality and 
relevance of HCV HRQL studies were assessed against FDA and EMEA guidelines. 
The review facilitated construction of a conceptual framework of HCV HRQL. The 
framework was compared against HRQL measures used in HCV research, including 
the SF-36, Hepatitis Quality of Life Questionnaire (HQLQ), Chronic Liver Disease 
Questionnaire (CLDQ), Liver Disease Symptom Index (LDSI 2.0), and Hepatitis B 
Quality of Life instrument (HBQOL). RESULTS: Numerous dimensions encompassing 
the HCV HRQL experience were not adequately represented by common measures. 
Absent from the measures were consideration of treatment adherence and management, 
and management of side effects; HIV/HCV co-infection issues; drug addiction; resilience 
and coping; contagiousness and transmission-related issues; illness uncertainty and 
unpredictability; and changes in body image. HCV dimensions needing further attention 
were liver disease severity; psychiatric complications including emotional volatility; 
cognitive impairment during daily activity; sexual dysfunction; the multidimensional 
nature of stigma; and fatigue variability. CONCLUSIONS: The disease-speciﬁ c experi-
ence of HCV is not fully addressed by any single existing measure. An HCV HRQL 
instrument that is sensitive to the identiﬁ ed dimensions and issues would be of con-
siderable beneﬁ t. Such a measure would help health care providers plan individual 
interventions for problematic HRQL domains, as well as improve patient monitoring 
during treatment and clinical research trials, and contribute to determining the value 
and efﬁ cacy of treatment programs. 
URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies
PUK1
CONTRAST-INDUCED NEPHROPATHY IN PATIENTS WITH CHRONIC 
KIDNEY DISEASE UNDERGOING COMPUTED TOMOGRAPHY: A 
COMPARATIVE SAFETY META-ANALYSIS OF RANDOMIZED 
CONTROLLED TRIALS
Catalá-López F1, Arana E2
1Spanish Medicines and Healthcare Products Agency (AEMPS), Madrid, Spain; 2Fundación 
Instituto de Investigación en Servicios de Salud, Valencia, Spain
OBJECTIVES: We conducted a systematic review and meta-analysis comparing the 
incidence of contrast-induced nephropathy (CIN) in patients at risk with chronic 
kidney disease (CKD) undergoing computed tomography (CT). METHODS: Random-
ized controlled clinical trials designated to evaluate the nephrotoxicity related to 
iso-osmolar contrast media (IOCM) compared to low-osmolar contrast media 
(LOCM) were searched in the following electronic databases: PubMed/MEDLINE, 
EMBASE, ISI Web of Knowledge and Virtual Health Library (BVS-BIREME), as well 
as abstracts presented at related scientiﬁ c societies meetings. Prior to data extraction, 
deﬁ nitions of nephrotoxicity were established. We applied a random effects model of 
DerSimonian and Laird, with heterogeneity (Q statistic), publication bias (Egger and 
Begg test) and sensitivity analyses. RESULTS: Five studies were included with 716 
randomized patients. When CIN was deﬁ ned as increased serum creatinine (SCr) ≥ 
25%, the relative risk (RR) was 0.71 (CI95% 0.40 to 1.26)—in favor of IOCM—and 
when it was deﬁ ned as SCr ≥ 0.5 mg/dL it showed a RR 1.48 (CI95% 0.37 to 5.87)—
favoring LOCM—in the four studies used this criterion. CONCLUSIONS: In patients 
with CKD undergoing CT there is a similar risk of CIN with the administration of 
any contrast media studied. CIN incidence depends on the chosen criteria and is lower 
with the deﬁ nition of SCr ≥ 0.5 mg/dL at 24–72 h.
PUK2
COMORBIDITY EFFECT ON HOSPITAL READMISSION RATES IN 
PATIENTS WITH RENAL FAILURE
Rhee Y1, Walker DR2, Inglese G2
1Northwestern University, Chicago, IL, USA; 2Baxter Healthcare Corporation, McGaw Park, 
IL, USA
OBJECTIVES: To examine the effects of comorbidities on the hospital readmission 
rate in renal failure (RF) patients on dialysis. METHODS: We used 2005–2007 U.S. 
MarketScan claims database to identify RF patients under 64 years old. RF dialysis 
patients were identiﬁ ed using ICD-9 and CPT codes. RF patients had to be continu-
ously eligible for at least 6 months after the initial dialysis diagnosis date (index dates). 
Comorbidity scores were measured by the Charlson Comorbidity Index (CCI). We 
identiﬁ ed readmission rates to the hospital within 15 days after the index date. 
ANOVA tests and logistic regression were performed to compare outcomes by CCI. 
RESULTS: A total of 6117 patients were diagnosed with RF. Among those who initi-
ated dialysis treatment, 13.9% and 86.1% were treated with peritoneal dialysis and 
hemodialysis, respectively. Over half of all patients were male (55.2%) and the average 
age was 52.4 years. The most frequent comorbid conditions were hypertension 
(69.1%), diabetes (34.5%), congestive heart failure (CHF) (26.3%), and anemia (26.4 
%). Most patients had low (78%, score < = 3) or moderate (12.0%, score 4–5) CCI 
scores. 7.2% of patients had a score of 6–7 and 125 (2.0%) had a score > 8. Older 
patients had signiﬁ cantly more severe CCI scores (P < 0.001). The average age in the 
moderate and severe co-morbidity groups was 51.7 and 57.4 years old, respectively. 
a total of 1.3% of RF dialysis patients were readmitted to the hospital within 15 days. 
Their readmission rates were signiﬁ cantly associated with the CCI score (P < 0.001). 
Patients over age 50 were signiﬁ cantly more likely to readmit to the hospital (P < 
0.001). Those with a higher CCI score were more likely to readmit to the hospital 
within 15 days (moderate group OR. 3.0, P < 0.001, very high group OR 4.04, P < 
0.001). CONCLUSIONS: For patients with RF, the presence of severe comorbid 
physical conditions was signiﬁ cantly associated with hospital readmission within 15 
days.
PUK3
ASSESSMENT OF COMORBIDITIES IN PATIENTS WITH OVERACTIVE 
BLADDER (OAB) DISORDER: AN ELECTRONIC MEDICAL RECORD (EMR) 
DATA ANALYSIS
Asche C1, Kim J2, Chakravarti P3, Andersson KE4
1University of Utah College of Pharmacy, Salt Lake City, UT, USA; 2University of Utah, Salt 
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OBJECTIVES: To compare OAB patients to non-OAB patients by assessing their 
pre-existing comorbidities prior to their OAB diagnosis or ﬁ rst OAB treatment. 
METHODS: This retrospective cohort study used the General Electric (GE) Centricity 
EMR database. The study subjects were from between January 1, 1996 to March 30, 
2007. The index date for OAB patients was deﬁ ned as the date of their ﬁ rst prescrip-
tion for an antimuscarinic agent or a diagnosis for OAB identiﬁ ed by ICD-9 codes. 
The index date of non-OAB subjects without diagnosis or pharmacy claim was deﬁ ned 
as a year after the ﬁ rst activity date in the EMR. Subjects ≥18 years old were included 
and had 395 days of continuous enrollment before and after the index date. Non-OAB 
subjects were matched to OAB subjects on 1:1 propensity score matching based on 
age, body mass index (BMI) and gender at baseline. Two linear regressions were 
constructed using the outcome variables of the Charlson Comorbidity Index (CCI), 
using ICD-9 codes, and the Chronic Disease Score (CDS), using prescribed drugs, 
respectfully. RESULTS: There were 38,739 OAB subjects [mean age 61.18 (SD:13.26) 
years; 85.67% women] and 38,739 matched non-OAB subjects [mean age 61.17 (SD:
13.24) years; 85.70% women]. Patients with OAB had higher mean CCI and 
CDS than subjects without OAB [(CCI: 1.17 vs. 1.11 (p-value < 0.001); CDS: 
2.95 vs. 1.74 (p-value < 0.001)]. After controlling for other covariates, the linear 
regressions (n = 22,544) showed that OAB patients had higher CCI and CDS than 
subjects without OAB by 0.037 (p-value < 0.001) and by 0.881 (p-value: < 0.001), 
respectively. CONCLUSIONS: This study determined that pre-existing comorbidities 
were more prevalent in OAB patients than in non-OAB patients. These comorbidities 
should to be taken into account when making the decision on the most appropriate 
treatment option for each individual patient.
PUK4
A SYSTEMATIC REVIEW OF IMMUNOSUPPRESSIVE REGIMENS IN 
LOWER IMMUNOLOGICAL RISK RENAL TRANSPLANT RECIPIENTS
Kang MH, Kim HJ, Ko RK, Ko SK
Pﬁ zer Pharmaceuticals Korea Ltd., Seoul, South Korea
OBJECTIVES: In this study, we conducted a systematic review of three immunosup-
pressive regimens in lower risk renal transplantation and compared their efﬁ cacy. 
METHODS: MEDLINE were searched and two independent reviewers assessed 
studies. We limited the search to English, Randomized controlled trial, Human and 
publication between January 1, 1999~May 31, 2010. Studies which were conducted 
with adult renal transplant patients (>18 years) with lower immunological risk were 
included. Sirolimus + steroid regimen with 3 months cyclosporine, and CNI (Calci-
neurin inhibitor: cyclosporine or tacrolimus) regimen with MMF and steroid were 
eligible for inclusion. a total of 434 studies were retrieved from MEDLINE ﬁ rstly. By 
reviewing title, abstracts and full text, 10 studies were eligible for the inclusion ﬁ nally. 
As outcome data, we extracted patient survival and graft survival. RESULTS: There 
was no head-to-head clinical trial which compared the three regimens concurrently. 
But results from 2 studies shows trend of higher patient and graft survival with low 
dose CNI regimen than standard dose cyclosporine. ELITE-Symphony Study illus-
trated patient and graft survival of 96.5% and 89.3% for standard dose cyclosporine, 
98.2% and 93.1% for low dose cyclosporine, 97.2% and 94.2% for low dose tacro-
limus at 1 year. And CAESAR Study showed 97.1% and 92.4% for standard dose 
cyclosporine, 97.8% and 94.5% for low dose cyclosporine at 1 year. 5 reports from 
‘Rapamune Maintenance Regimen Study’ showed outcomes for sirolimus based 
regimen during 5 years. At 1 year, patient and graft survival were 98.1% and 97.2% 
and decreased thereafter. One study of tacrolimus based regimen reported 2-year 
